Novavax, Inc. (NVAX) vs Taysha Gene Therapies, Inc. (TSHA)

Novavax, Inc. and Taysha Gene Therapies, Inc. are both Biotechnology companies. Novavax, Inc. and Taysha Gene Therapies, Inc. are of similar size ($1.3B and $1.3B). Taysha Gene Therapies, Inc. grew revenue faster over the last twelve months: 19.0% against −61.3%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −18.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Novavax, Inc. leads on 8 and Taysha Gene Therapies, Inc. on 7.

Valuation

Metric NVAX TSHA Biotechnology median
P/E n/m n/m 10.01
P/S 3.19 138.07 9.02
P/B n/m 4.56 2.13
Price to free cash flow n/m n/m 24.99
EV/EBITDA n/m n/m 0.64
EV/Sales 2.39 106.23 9.01
Earnings yield (5.79%) (10.63%) (34.01%)
Free cash flow yield (18.74%) (8.88%) (24.62%)

Profitability

Metric NVAX TSHA Biotechnology median
Gross margin 78.01% 100.00% 70.18%
Operating margin (21.23%) 0.00% 0.00%
Net margin (18.64%) 0.00% 0.00%
Free cash flow margin (59.25%) 0.00% 0.00%
Return on equity 41.08% (54.18%) (50.72%)
Return on assets (7.42%) (41.52%) (45.56%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NVAX TSHA Biotechnology median
Revenue growth (TTM) (61.33%) 18.96% 7.42%
EPS growth (last fiscal year) 309.76% 5.56% 29.36%
Revenue growth, 5-year CAGR 18.76% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NVAX TSHA Biotechnology median
Debt to equity (1.35) 0.13 0.00
Current ratio 2.15 18.56 4.72
Net debt to EBITDA (1.04) 2.47 1.01

Dividend

Metric NVAX TSHA Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric NVAX TSHA Biotechnology median
Market cap 1.31b 1.30b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack